Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780

Veronique W T Ruiz Van Haperen, Gijsbert Veerman, Staffan Eriksson, Epie Boven, Alexander P A Stegmann, Mario Hermsen, Jan B. Vermorken, Herbert M. Pinedo, Godefridus J. Peters

Research output: Contribution to journalArticle

Abstract

2′,2′-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue with promising antitumor activity. In order to be active it must be phosphorylated by deoxycytidine kinase (dCK). We induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concentrations of dFdCyd. The IC50, defined as the concentration of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000. Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd. AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2′-deoxycytidine, and 2-chlorodeoxyadenosine. There was no specific dCK activity in extracts from AG6000 cells. Western blot analysis using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell extracts. Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs. Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000. The latter cell line was also cross-resistant to 2′,2′-difluorodeoxyuridine, the deamination product of dFdCyd. Additionally, cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was observed. This was not associated with the induction of P-glycoprotein, as determined by the RNase protection assay. Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors. No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors. These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.

Original languageEnglish (US)
Pages (from-to)4138-4143
Number of pages6
JournalCancer Research
Volume54
Issue number15
StatePublished - Aug 1 1994
Externally publishedYes

Fingerprint

gemcitabine
Deoxycytidine Kinase
Carcinoma
Cell Line
decitabine
Cell Extracts
Base Pairing
Cladribine
Phenotype
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ruiz Van Haperen, V. W. T., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P. A., Hermsen, M., ... Peters, G. J. (1994). Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Research, 54(15), 4138-4143.

Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. / Ruiz Van Haperen, Veronique W T; Veerman, Gijsbert; Eriksson, Staffan; Boven, Epie; Stegmann, Alexander P A; Hermsen, Mario; Vermorken, Jan B.; Pinedo, Herbert M.; Peters, Godefridus J.

In: Cancer Research, Vol. 54, No. 15, 01.08.1994, p. 4138-4143.

Research output: Contribution to journalArticle

Ruiz Van Haperen, VWT, Veerman, G, Eriksson, S, Boven, E, Stegmann, APA, Hermsen, M, Vermorken, JB, Pinedo, HM & Peters, GJ 1994, 'Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780', Cancer Research, vol. 54, no. 15, pp. 4138-4143.
Ruiz Van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Research. 1994 Aug 1;54(15):4138-4143.
Ruiz Van Haperen, Veronique W T ; Veerman, Gijsbert ; Eriksson, Staffan ; Boven, Epie ; Stegmann, Alexander P A ; Hermsen, Mario ; Vermorken, Jan B. ; Pinedo, Herbert M. ; Peters, Godefridus J. / Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. In: Cancer Research. 1994 ; Vol. 54, No. 15. pp. 4138-4143.
@article{c183c62e34754d539df527f8095ea334,
title = "Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780",
abstract = "2′,2′-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue with promising antitumor activity. In order to be active it must be phosphorylated by deoxycytidine kinase (dCK). We induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concentrations of dFdCyd. The IC50, defined as the concentration of dFdCyd causing 50{\%} growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000. Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd. AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2′-deoxycytidine, and 2-chlorodeoxyadenosine. There was no specific dCK activity in extracts from AG6000 cells. Western blot analysis using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell extracts. Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs. Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000. The latter cell line was also cross-resistant to 2′,2′-difluorodeoxyuridine, the deamination product of dFdCyd. Additionally, cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was observed. This was not associated with the induction of P-glycoprotein, as determined by the RNase protection assay. Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors. No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors. These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.",
author = "{Ruiz Van Haperen}, {Veronique W T} and Gijsbert Veerman and Staffan Eriksson and Epie Boven and Stegmann, {Alexander P A} and Mario Hermsen and Vermorken, {Jan B.} and Pinedo, {Herbert M.} and Peters, {Godefridus J.}",
year = "1994",
month = "8",
day = "1",
language = "English (US)",
volume = "54",
pages = "4138--4143",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780

AU - Ruiz Van Haperen, Veronique W T

AU - Veerman, Gijsbert

AU - Eriksson, Staffan

AU - Boven, Epie

AU - Stegmann, Alexander P A

AU - Hermsen, Mario

AU - Vermorken, Jan B.

AU - Pinedo, Herbert M.

AU - Peters, Godefridus J.

PY - 1994/8/1

Y1 - 1994/8/1

N2 - 2′,2′-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue with promising antitumor activity. In order to be active it must be phosphorylated by deoxycytidine kinase (dCK). We induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concentrations of dFdCyd. The IC50, defined as the concentration of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000. Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd. AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2′-deoxycytidine, and 2-chlorodeoxyadenosine. There was no specific dCK activity in extracts from AG6000 cells. Western blot analysis using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell extracts. Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs. Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000. The latter cell line was also cross-resistant to 2′,2′-difluorodeoxyuridine, the deamination product of dFdCyd. Additionally, cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was observed. This was not associated with the induction of P-glycoprotein, as determined by the RNase protection assay. Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors. No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors. These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.

AB - 2′,2′-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analogue with promising antitumor activity. In order to be active it must be phosphorylated by deoxycytidine kinase (dCK). We induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concentrations of dFdCyd. The IC50, defined as the concentration of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000. Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd. AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2′-deoxycytidine, and 2-chlorodeoxyadenosine. There was no specific dCK activity in extracts from AG6000 cells. Western blot analysis using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell extracts. Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs. Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000. The latter cell line was also cross-resistant to 2′,2′-difluorodeoxyuridine, the deamination product of dFdCyd. Additionally, cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was observed. This was not associated with the induction of P-glycoprotein, as determined by the RNase protection assay. Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors. No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors. These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0028067217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028067217&partnerID=8YFLogxK

M3 - Article

C2 - 8033147

AN - SCOPUS:0028067217

VL - 54

SP - 4138

EP - 4143

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -